Since the emergence of COVID-19, caused by the SARS-CoV-2 virus at the end of 2019,
there has been an explosion of vaccine development. By 24 September 2020, a staggering …

Enabled by new approaches for rapid identification and selection of human monoclonal
antibodies, atomic-level structural information for viral surface proteins, and capacity for …

Enveloped viruses enter cells by inducing fusion of viral and cellular membranes, a process
catalyzed by a specialized membrane-fusion protein expressed on their surface. This review …

Respiratory syncytial virus (RSV) is responsible for a significant proportion of global
morbidity and mortality affecting young children and older adults. In the aftermath of formalin …

There is currently no licensed vaccine for respiratory syncytial virus (RSV). Here, we assess
the effect of RSV fusion protein (F) conformation on B cell responses in a post hoc …

A key aspect of successful viral vaccine design is the elicitation of neutralizing antibodies
targeting viral attachment and fusion glycoproteins that embellish viral particles. This …

Abstract Structure-based design of vaccines, particularly the iterative optimization used so
successfully in the structure-based design of drugs, has been a long-sought goal. We …

The respiratory syncytial virus (RSV) F glycoprotein is a class I fusion protein that mediates
viral entry and is a major target of neutralizing antibodies. Structures of prefusion forms of …

Deep learning has led to incredible breakthroughs in areas of research, from self-driving
vehicles to solutions, to formal mathematical proofs. In the biomedical sciences, however …

Parainfluenza virus types 1–4 (PIV1–4) are highly infectious human pathogens, of which
PIV3 is most commonly responsible for severe respiratory illness in newborns, elderly, and …